To study the role of IL-33 in BPD, we treated C57BL/6 mice with mouse recombinant IL-33 (0.5 μg/mouse/day intraperitoneally) or anti-sST2 antibody (1 μg/mouse/day intraperitoneally) every alternate day from day 7 after birth and sacrificed mice on day 14 (Figure 3(a)). Here, IL33 is linked to bronchopulmonary dysplasia.